Apellis Pharmaceuticals, Inc. (APLS)
NASDAQ: APLS · Real-Time Price · USD
17.55
+0.06 (0.31%)
Apr 24, 2025, 4:00 PM EDT - Market closed
Apellis Pharmaceuticals Revenue
In the year 2024, Apellis Pharmaceuticals had annual revenue of $781.37M with 97.02% growth. Apellis Pharmaceuticals had revenue of $212.53M in the quarter ending December 31, 2024, with 45.19% growth.
Revenue (ttm)
$781.37M
Revenue Growth
+97.02%
P/S Ratio
2.78
Revenue / Employee
$1,100,517
Employees
710
Market Cap
2.20B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 781.37M | 384.78M | 97.02% |
| Dec 31, 2023 | 396.59M | 321.17M | 425.83% |
| Dec 31, 2022 | 75.42M | 8.86M | 13.31% |
| Dec 31, 2021 | 66.56M | -184.08M | -73.44% |
| Dec 31, 2020 | 250.65M | - | - |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 63.92B |
| AbbVie | 56.33B |
| AstraZeneca | 54.07B |
| Novartis AG | 51.72B |
| Eli Lilly and Company | 45.04B |
| Thermo Fisher Scientific | 42.90B |
APLS News
- 3 days ago - Apellis Announces Craig Wheeler to Join the Board of Directors - GlobeNewsWire
- 23 days ago - FDA Reviews Kidney Disease Drug From Apellis Pharmaceuticals - Benzinga
- 23 days ago - Apellis Announces FDA Acceptance and Priority Review of the Supplemental New Drug Application for EMPAVELI® (pegcetacoplan) for C3G and Primary IC-MPGN - GlobeNewsWire
- 7 weeks ago - Apellis Pharmaceuticals: A Mixed Bag - Seeking Alpha
- 7 weeks ago - Apellis Lead Drug Pegcetacoplan Represents Differentiated Asset: JP Morgan Analyst - Benzinga
- 7 weeks ago - Apellis Pharmaceuticals, Inc. (APLS) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 7 weeks ago - Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results - GlobeNewsWire
- 2 months ago - Apellis Pharmaceuticals to Present at the TD Cowen 45th Annual Health Care Conference - GlobeNewsWire